Hepatitis B Virus Reactivation After Cytotoxic Chemotherapy: The Disease and Its Prevention

Ayse L. Mindikoglu, Arie Regev, Eugene R Schiff

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

Reactivation of hepatitis B virus (HBV) is a well-recognized complication in patients with chronic HBV infection who receive cytotoxic or immunosuppressive therapy. In most cases, reactivations occur in patients who are carriers of HBV infection showing positive hepatitis B surface antigen (HBsAg). Reactivation also may occur in patients with resolved infection who are HBsAg negative, anti-HBs positive, and anti-hepatitis B core positive. HBV reactivations can lead to severe flares that may be life-threatening unless recognized and treated promptly. Physician awareness is essential because prophylactic antiviral treatment can diminish the occurrence and improve the outcome of such episodes. Patients undergoing cytotoxic therapy should be checked routinely for HBV serologic markers and serum HBV DNA levels. Patients who are HBV carriers or anti-hepatitis B core positive should be monitored closely during and after the administration of cytotoxic chemotherapy. Prophylactic treatment with a nucleoside or nucleotide analogue should be considered strongly to prevent HBV reactivation in these patients.

Original languageEnglish
Pages (from-to)1076-1081
Number of pages6
JournalClinical Gastroenterology and Hepatology
Volume4
Issue number9
DOIs
StatePublished - Sep 1 2006

Fingerprint

Hepatitis B virus
Drug Therapy
Virus Diseases
Hepatitis B Surface Antigens
Hepatitis B
Chronic Hepatitis B
Therapeutics
Immunosuppressive Agents
Nucleosides
Antiviral Agents
Nucleotides
Biomarkers
Physicians
DNA
Infection

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Hepatitis B Virus Reactivation After Cytotoxic Chemotherapy : The Disease and Its Prevention. / Mindikoglu, Ayse L.; Regev, Arie; Schiff, Eugene R.

In: Clinical Gastroenterology and Hepatology, Vol. 4, No. 9, 01.09.2006, p. 1076-1081.

Research output: Contribution to journalArticle

@article{36b0719cace549709bbf555d8fabe48c,
title = "Hepatitis B Virus Reactivation After Cytotoxic Chemotherapy: The Disease and Its Prevention",
abstract = "Reactivation of hepatitis B virus (HBV) is a well-recognized complication in patients with chronic HBV infection who receive cytotoxic or immunosuppressive therapy. In most cases, reactivations occur in patients who are carriers of HBV infection showing positive hepatitis B surface antigen (HBsAg). Reactivation also may occur in patients with resolved infection who are HBsAg negative, anti-HBs positive, and anti-hepatitis B core positive. HBV reactivations can lead to severe flares that may be life-threatening unless recognized and treated promptly. Physician awareness is essential because prophylactic antiviral treatment can diminish the occurrence and improve the outcome of such episodes. Patients undergoing cytotoxic therapy should be checked routinely for HBV serologic markers and serum HBV DNA levels. Patients who are HBV carriers or anti-hepatitis B core positive should be monitored closely during and after the administration of cytotoxic chemotherapy. Prophylactic treatment with a nucleoside or nucleotide analogue should be considered strongly to prevent HBV reactivation in these patients.",
author = "Mindikoglu, {Ayse L.} and Arie Regev and Schiff, {Eugene R}",
year = "2006",
month = "9",
day = "1",
doi = "10.1016/j.cgh.2006.05.027",
language = "English",
volume = "4",
pages = "1076--1081",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "9",

}

TY - JOUR

T1 - Hepatitis B Virus Reactivation After Cytotoxic Chemotherapy

T2 - The Disease and Its Prevention

AU - Mindikoglu, Ayse L.

AU - Regev, Arie

AU - Schiff, Eugene R

PY - 2006/9/1

Y1 - 2006/9/1

N2 - Reactivation of hepatitis B virus (HBV) is a well-recognized complication in patients with chronic HBV infection who receive cytotoxic or immunosuppressive therapy. In most cases, reactivations occur in patients who are carriers of HBV infection showing positive hepatitis B surface antigen (HBsAg). Reactivation also may occur in patients with resolved infection who are HBsAg negative, anti-HBs positive, and anti-hepatitis B core positive. HBV reactivations can lead to severe flares that may be life-threatening unless recognized and treated promptly. Physician awareness is essential because prophylactic antiviral treatment can diminish the occurrence and improve the outcome of such episodes. Patients undergoing cytotoxic therapy should be checked routinely for HBV serologic markers and serum HBV DNA levels. Patients who are HBV carriers or anti-hepatitis B core positive should be monitored closely during and after the administration of cytotoxic chemotherapy. Prophylactic treatment with a nucleoside or nucleotide analogue should be considered strongly to prevent HBV reactivation in these patients.

AB - Reactivation of hepatitis B virus (HBV) is a well-recognized complication in patients with chronic HBV infection who receive cytotoxic or immunosuppressive therapy. In most cases, reactivations occur in patients who are carriers of HBV infection showing positive hepatitis B surface antigen (HBsAg). Reactivation also may occur in patients with resolved infection who are HBsAg negative, anti-HBs positive, and anti-hepatitis B core positive. HBV reactivations can lead to severe flares that may be life-threatening unless recognized and treated promptly. Physician awareness is essential because prophylactic antiviral treatment can diminish the occurrence and improve the outcome of such episodes. Patients undergoing cytotoxic therapy should be checked routinely for HBV serologic markers and serum HBV DNA levels. Patients who are HBV carriers or anti-hepatitis B core positive should be monitored closely during and after the administration of cytotoxic chemotherapy. Prophylactic treatment with a nucleoside or nucleotide analogue should be considered strongly to prevent HBV reactivation in these patients.

UR - http://www.scopus.com/inward/record.url?scp=33748173669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748173669&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2006.05.027

DO - 10.1016/j.cgh.2006.05.027

M3 - Article

C2 - 16861051

AN - SCOPUS:33748173669

VL - 4

SP - 1076

EP - 1081

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 9

ER -